Skip to main content

MPs to investigate regional disparities in cancer outcomes

5 November 2021

In its fourth evidence session, the inquiry into cancer services will hear from patients, doctors, charity leaders, and researchers.

The Committee will seek to understand why certain areas have better access to clinical trials, more curative treatment options, and more advanced services than others. Questions are likely to be asked over why early diagnosis rates vary by as much as 16% between different areas. MPs are also likely to examine why survival rates are lower for more deprived socio-economic groups. 

Purpose of the session

The Committee is also expected to consider how less survivable and less common cancers fit into the NHS’s long-term cancer plan. This includes how effectively the Government’s investment in new community diagnostic hubs will improve diagnosis of less common and less survivable cancers. 

Witnesseses

Tuesday 9 November

At 10.00am

  • Katy Hall, cancer patient

At 10.20am

  • Professor David Baldwin, Chair at Lung Cancer Clinical Expert Group
  • Anna Jewell, Chair at Less Survivable Cancers Taskforce
  • Jane Lyons, Chief Executive at Cancer52

At 11.10am

  • Professor David Shackley, Director at Greater Manchester Cancer
  • Ian Vousden, Programme Director at Kent and Medway Cancer Alliance
  • Sarah Stevens, Deputy Director, National Disease Registration Service, NHS Digital

Further information

Image: unsplash